Dr Tho Lye Mun is a senior Consultant Clinical Oncologist at Beacon Hospital, Petaling Jaya, Selangor, Malaysia. He graduated from the University of Sydney, Australia in 1998 and thereafter worked in premiere UK institutions namely the Beatson Oncology Centre, Glasgow and the Royal Marsden Cancer Hospital, London. He returned to Malaysia as an Associate Professor in University of Malaya (UM) and then entered private practice in 2014.

Dr Tho completed internal medicine training – MRCP (UK) and clinical oncology training – FRCR (UK) before earning a full scholarship to complete a PhD in Molecular Oncology at the University of Glasgow. He currently serves as the Head of Oncology at Beacon Hospital, President of the Lung Cancer Network of Malaysia and Board Member of the Asian Society of Neuro-Oncology and Asia Pacific Coalition against Lung Cancer.

Dr Tho specialises in advanced cancer treatments, especially immunotherapy and molecular targeted therapy. He is a pioneer in the field of immunotherapy and is the first oncologist to use PD-1 inhibitors in Malaysia in 2016. He is also a pioneer in precision radiotherapy and stereotactic radiosurgery (SRS)in Malaysia with expertise in True Beam Hyperarc SRS, Cyberknife and Gammaknife. Dr Tho is the first to publish outcomes of Cyberknife SRS for brain metastases in Malaysia in 2015. His practice also includes SBRT, IGRT, IMRT and VMAT. He has published his work in top tier journals such as Lancet Oncology, Annals of Oncology and Journal of Thoracic Oncology.

As President of the Lung Cancer Network of Malaysia (LCNM) Dr Tho is very active in community talk and engagements to promote screening, early detection and informing the public about the latest developments in the field of lung cancer.

Dr Tho is committed to delivering personalised, innovative, evidence-based oncology treatments, helping patients achieve the best possible outcomes with a dedication to their quality of life and patient well-being.